🚀 VC round data is live in beta, check it out!
Curasight Valuation Multiples
Discover revenue and EBITDA valuation multiples for Curasight and similar public comparables like Biodesix, Scope Fluidics, Fonar, Hyperfine and more.
Curasight Overview
About Curasight
Curasight AS is a clinical-stage biotech company committed to improving both the diagnosis and the treatment of certain types of cancer. The company is focused on generating data with both uTRACE and uTREAT in cancers, including prostate cancer and glioblastoma (brain cancer), neuroendocrine tumors (NET), head and neck cancer, non small cell lung cancer (NSCLC), and pancreatic cancer.
Founded
2013
HQ
Employees
4
Website
Financials (LTM)
EV
$118M
Curasight Financials
Curasight reported last 12-month negative EBITDA of ($9M).
In the same LTM period, Curasight generated ($9M) in EBITDA losses and had net loss of ($8M).
Revenue (LTM)
Curasight P&L
In the most recent fiscal year, Curasight reported revenue of — and EBITDA of ($8M).
Curasight expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | — | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA | ($9M) | XXX | ($8M) | XXX | XXX | XXX |
| Net Profit | ($8M) | XXX | ($8M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Curasight Stock Performance
Curasight has current market cap of $123M, and enterprise value of $118M.
Market Cap Evolution
Curasight's stock price is $2.56.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $118M | $123M | -0.5% | XXX | XXX | XXX | $-0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCurasight Valuation Multiples
Curasight trades at (12.9x) EV/EBITDA.
Curasight Financial Valuation Multiples
As of March 27, 2026, Curasight has market cap of $123M and EV of $118M.
Equity research analysts estimate Curasight's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Curasight has a P/E ratio of (15.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $123M | XXX | $123M | XXX | XXX | XXX |
| EV (current) | $118M | XXX | $118M | XXX | XXX | XXX |
| EV/EBITDA | (12.9x) | XXX | (14.0x) | XXX | XXX | XXX |
| EV/EBIT | (13.1x) | XXX | (13.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (15.4x) | XXX | XXX | XXX |
| P/E | (15.0x) | XXX | (15.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (14.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Curasight Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Curasight Margins & Growth Rates
Curasight's revenue in the last fiscal year grew by —.
Curasight Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 9% | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Curasight Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Biodesix | XXX | XXX | XXX | XXX | XXX | XXX |
| Scope Fluidics | XXX | XXX | XXX | XXX | XXX | XXX |
| Fonar | XXX | XXX | XXX | XXX | XXX | XXX |
| Hyperfine | XXX | XXX | XXX | XXX | XXX | XXX |
| Infinitt Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Curasight M&A Activity
Curasight acquired XXX companies to date.
Last acquisition by Curasight was on XXXXXXXX, XXXXX. Curasight acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Curasight
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCurasight Investment Activity
Curasight invested in XXX companies to date.
Curasight made its latest investment on XXXXXXXX, XXXXX. Curasight invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Curasight
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Curasight
| When was Curasight founded? | Curasight was founded in 2013. |
| Where is Curasight headquartered? | Curasight is headquartered in Denmark. |
| How many employees does Curasight have? | As of today, Curasight has over 4 employees. |
| Is Curasight publicly listed? | Yes, Curasight is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Curasight? | Curasight trades under CURAS ticker. |
| When did Curasight go public? | Curasight went public in 2020. |
| Who are competitors of Curasight? | Curasight main competitors are Biodesix, Scope Fluidics, Fonar, Hyperfine. |
| What is the current market cap of Curasight? | Curasight's current market cap is $123M. |
| Is Curasight profitable? | No, Curasight is not profitable. |
| What is the current EBITDA of Curasight? | Curasight has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Curasight? | Current EBITDA multiple of Curasight is (12.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.